Bilosomes: the answer to oral vaccine delivery?

Abstract Background: Viral infection caused by Hepatitis B is transmitted by permucosal or parenteral exposure and also one of the prime causes of hepatocellular carcinoma and liver cirrhosis. Objectives: M-cell targeting acid-resistant oral vaccine delivery have been formulated for immunization against Hepatitis B infection. Methods: Cationic solid lipid nanoparticles (cSLNs) were prepared utilizing solvent injection technique. Hepatitis B surface antigen (HBsAg) loaded alginate coated cSLNs were anchored with lipopolysaccharide (LPS). SDS-PAGE was performed to evaluate acid degradation protection of prepared formulation. Induction of immunity produced by prepared nanoparticle for Hepatitis B was determined on female Balb/c mice followed by ELISA assays for assessing anti-HBsAg IgG/IgA antibodies in mucosal fluids. Results: Sustained release of HBsAg (60.66 %) has been exhibited from alginate coated cSLNs in comparison to cSLNs without alginate coating (97.72 %) after 48 h. The production of anti-HBs titer in intestinal, salivary and vaginal secretions was 3.41 IU/ml, 3.1 IU/ml and 2.51 IU/ml respectively in comparison to the control group. Integrity of the M-cells has been maintained after binding with SLN, and oral administration delivered the antigen to the desired site of gut. Conclusion: It was found effective in producing antibodies in mucosal immunization against Hepatitis B virus. So, this formulation could be used as a promising alternative preexisting vaccine to prevent Hepatitis B infection.

Download Full-text

Dressing liposomal particles with chitosan and poly(vinylic alcohol) for oral vaccine delivery

Journal of Liposome Research ◽

10.3109/08982101003735988 ◽

2010 ◽

Vol 21 (1) ◽

pp. 38-45 ◽

Cited By ~ 13

Author(s):

Vanessa C. Rescia ◽

Célia S. Takata ◽

Pedro S. de Araujo ◽

Maria H. Bueno da Costa

Keyword(s):

Oral Vaccine ◽

Vaccine Delivery

Download Full-text

Comparison and process optimization of PLGA, chitosan and silica nanoparticles for potential oral vaccine delivery

Therapeutic Delivery ◽

10.4155/tde-2019-0038 ◽

2019 ◽

Vol 10 (8) ◽

pp. 493-514 ◽

Cited By ~ 1

Author(s):

Muhammad K Amin ◽

Joshua S Boateng

Keyword(s):

Silica Nanoparticles ◽

Process Parameters ◽

Functional Performance ◽

Oral Vaccine ◽

Polymer Concentration ◽

Vaccine Delivery ◽

Inorganic Materials ◽

Protein Encapsulation ◽

Scanning Transmission

Aim: The study compared performance of nanoparticles prepared from synthetic organic, natural organic and inorganic materials as vaccine delivery platforms. Materials & methods: Various formulation (concentration, polymer/silica:surfactant ratio, solvent) and process parameters (homogenization speed and time, ultrasonication) affecting functional performance characteristics of poly(lactic- co-glycolic acid) (PLGA), chitosan and silica-based nanoparticles containing bovine serum albumin were investigated. Nanoparticles were characterized using dynamic light scattering, x-ray diffraction, scanning/transmission electron microscopy, Fourier transform infrared spectroscopy and in vitro protein release. Results: Critical formulation parameters were surfactant concentration (PLGA, silica) and polymer concentration (chitosan). Optimized nanoparticles were spherical in shape with narrow size distribution and size ranges of 100–300 nm (blank) and 150–400 nm (protein loaded). Protein encapsulation efficiency was 26–75% and released within 48 h in a sustained manner. Conclusion: Critical formulation and process parameters affected size of PLGA, chitosan and silica nanoparticles and protein encapsulation, while silica produced the smallest and most stable nanoparticles.

Download Full-text

Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics

The Annual Review of Pharmacology and Toxicology ◽

10.1146/annurev-pharmtox-030320-092348 ◽

2021 ◽

Vol 61 (1) ◽

pp. 517-540 ◽

Cited By ~ 1

Author(s):

Jacob William Coffey ◽

Gaurav Das Gaiha ◽

Giovanni Traverso

Keyword(s):

Oral Cavity ◽

Oral Vaccine ◽

Vaccine Delivery ◽

Mass Vaccination ◽

Oral Vaccines ◽

Gi Tract ◽

Oral Vaccination ◽

Enteric Diseases ◽

Mucosal Surfaces ◽

Inactivated Vaccines

Oral vaccination enables pain-free and self-administrable vaccine delivery for rapid mass vaccination during pandemic outbreaks. Furthermore, it elicits systemic and mucosal immune responses. This protects against infection at mucosal surfaces, which may further enhance protection and minimize the spread of disease. The gastrointestinal (GI) tract presents a number of prospective mucosal inductive sites for vaccine targeting, including the oral cavity, stomach, and small intestine. However, currently available oral vaccines are effectively limited to live-attenuated and inactivated vaccines against enteric diseases. The GI tract poses a number of challenges,including degradative processes that digest biologics and mucosal barriers that limit their absorption. This review summarizes the approaches currently under development and future opportunities for oral vaccine delivery to established (intestinal) and relatively new (oral cavity, stomach) mucosal targets. Special consideration is given to recent advances in oral biologic delivery that offer promise as future platforms for the administration of oral vaccines.

Download Full-text

Peptide nanofiber–CaCO3 composite microparticles as adjuvant-free oral vaccine delivery vehicles

Journal of Materials Chemistry B ◽

10.1039/c5tb01623a ◽

2016 ◽

Vol 4 (9) ◽

pp. 1640-1649 ◽

Cited By ~ 13

Author(s):

Joshua D. Snook ◽

Charles B. Chesson ◽

Alex G. Peniche ◽

Sara M. Dann ◽

Adriana Paulucci ◽

...

Keyword(s):

Mucosal Immunity ◽

Oral Vaccine ◽

Vaccine Delivery ◽

Oral Vaccination ◽

Delivery Vehicles ◽

Gi Infections ◽

Mucosal Pathogens

To combat mucosal pathogens that cause gastrointestinal (GI) infections, local mucosal immunity is required which is best achieved through oral vaccination.

Download Full-text